Disc Medicine (NASDAQ:IRON) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Disc Medicine (NASDAQ:IRON) in a research report released on Wednesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $89.00 price target on the stock.

A number of other analysts have also recently weighed in on the stock. Wells Fargo & Company began coverage on shares of Disc Medicine in a research report on Thursday, August 22nd. They set an “overweight” rating and a $75.00 price target for the company. Wedbush reiterated an “outperform” rating and issued a $57.00 price objective on shares of Disc Medicine in a report on Friday, August 9th. Scotiabank assumed coverage on shares of Disc Medicine in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $62.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a report on Tuesday, October 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of Disc Medicine in a report on Monday, September 16th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $66.40.

Disc Medicine Stock Up 0.0 %

Shares of NASDAQ IRON opened at $46.01 on Wednesday. The firm has a fifty day moving average of $48.92 and a 200-day moving average of $42.13. Disc Medicine has a 52-week low of $25.60 and a 52-week high of $77.60. The stock has a market capitalization of $1.37 billion, a PE ratio of -12.54 and a beta of 0.59.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($1.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.08. Equities research analysts expect that Disc Medicine will post -4.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors have recently modified their holdings of IRON. Wellington Management Group LLP raised its stake in shares of Disc Medicine by 224.6% in the 4th quarter. Wellington Management Group LLP now owns 177,726 shares of the company’s stock valued at $10,265,000 after purchasing an additional 122,981 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Disc Medicine by 149.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 10,000 shares of the company’s stock valued at $578,000 after purchasing an additional 5,990 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Disc Medicine by 349.1% in the 1st quarter. Jennison Associates LLC now owns 193,240 shares of the company’s stock valued at $12,031,000 after purchasing an additional 150,209 shares in the last quarter. Swiss National Bank raised its stake in shares of Disc Medicine by 50.6% in the 1st quarter. Swiss National Bank now owns 23,800 shares of the company’s stock valued at $1,482,000 after purchasing an additional 8,000 shares in the last quarter. Finally, ProShare Advisors LLC acquired a new stake in shares of Disc Medicine in the 1st quarter valued at about $211,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.